Effect on RLS Symptom Severity After Switching to Neupro® in Patients Who Previously Experienced Augmentation
NCT ID: NCT01386944
Last Updated: 2018-04-04
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
102 participants
OBSERVATIONAL
2011-07-31
2013-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Non-interventional Study (NIS) in Patients With Restless Legs Syndrome in Daily Practise
NCT01113710
Effects of Neupro on Cardiovascular Observations in Patients With Restless Legs Syndrome
NCT01455012
A Study in Patients Suffering From Idiopathic Restless Legs Syndrome Who Responded to a Preceding, 6-month Treatment With Open-label Pramipexole Including Titration (0.125, 0.25, 0.5, 0.75 mg Orally q.n.)
NCT00152958
SWITCH:Restless Legs Patients Switched to Ropinirole From Pramipexole
NCT00344994
A Trial of Neupro® (Rotigotine Transdermal Patch) in Patients With Parkinson's Disease Undergoing Surgery
NCT00594464
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Neupro® Treatment
Routine treatment (1,2,3 mg/24 h) as per approved label in the European Union (EU).
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The patient must be experiencing augmentation due to a prior dopaminergic treatment
* The decision to prescribe Neupro® has been made by the physician independently of his/her decision to enroll the patient in the study
* Patient is informed and given ample time and opportunity to think about his/her participation in the study and has given written informed data consent
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
UCB Pharma
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
UCB Clinical Trial Call Center
Role: STUDY_DIRECTOR
+1 877 822 9493 (UCB)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
12
Berlin, , Germany
4
Bremen, , Germany
18
Dresden, , Germany
20
Flensburg, , Germany
1
Kassel, , Germany
11
Marburg, , Germany
17
Marburg, , Germany
2
Mönchengladbach, , Germany
6
Münster, , Germany
7
Regensburg, , Germany
21
Remscheid, , Germany
15
Schriesheim, , Germany
10
Schwalmstadt, , Germany
3
Schwerin, , Germany
8
Tübingen, , Germany
16
Ulm, , Germany
9
Ulm, , Germany
19
Westerstede, , Germany
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Trenkwalder C, Canelo M, Lang M, Schroeder H, Kelling D, Berkels R, Schollmayer E, Heidbrede T, Benes H. Management of augmentation of restless legs syndrome with rotigotine: a 1-year observational study. Sleep Med. 2017 Feb;30:257-265. doi: 10.1016/j.sleep.2015.10.006. Epub 2015 Nov 11.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SP1009
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.